Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
Vucic S, Menon P, Huynh W, Mahoney C, Ho KS, Hartford A, Rynders A, Evan J, Evan J, Ligozio S, Glanzman R, Hotchkin MT, Kiernan MC. Vucic S, et al. Among authors: glanzman r. EClinicalMedicine. 2023 Jun 8;60:102036. doi: 10.1016/j.eclinm.2023.102036. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396808 Free PMC article.
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.
Ren J, Dewey RB 3rd, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB Jr, Greenberg BM. Ren J, et al. Among authors: glanzman r. J Nanobiotechnology. 2023 Dec 13;21(1):478. doi: 10.1186/s12951-023-02236-z. J Nanobiotechnology. 2023. PMID: 38087362 Free PMC article. Clinical Trial.
Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials.
Ren J, Dewey RB 3rd, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB Jr, Greenberg BM. Ren J, et al. Among authors: glanzman r. J Nanobiotechnology. 2024 Jan 3;22(1):16. doi: 10.1186/s12951-023-02269-4. J Nanobiotechnology. 2024. PMID: 38167088 Free PMC article. No abstract available.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Hartung HP, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, Prados F, MacManus D, Schneble HM, Lambert E, Porchet H, Glanzman R, Warne D, Curtin F, Kornmann G, Buffet B, Kremer D, Küry P, Leppert D, Rückle T, Barkhof F. Hartung HP, et al. Among authors: glanzman r. Mult Scler. 2022 Mar;28(3):429-440. doi: 10.1177/13524585211024997. Epub 2021 Jul 9. Mult Scler. 2022. PMID: 34240656 Free article. Clinical Trial.
Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease.
Frohman EM, Villemarette-Pittman NR, Rodriguez A, Glanzman R, Rugheimer S, Komogortsev O, Zamvil SS, Cruz RA, Varkey TC, Frohman AN, Frohman AR, Parsons MS, Konkle EH, Frohman TC. Frohman EM, et al. Among authors: glanzman r. J Neurol Sci. 2021 Jul 15;426:117463. doi: 10.1016/j.jns.2021.117463. Epub 2021 Apr 20. J Neurol Sci. 2021. PMID: 33971376 Free PMC article. Review.
Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression.
Vucic S, Kiernan MC, Menon P, Huynh W, Rynders A, Ho KS, Glanzman R, Hotchkin MT. Vucic S, et al. Among authors: glanzman r. BMJ Open. 2021 Jan 11;11(1):e041479. doi: 10.1136/bmjopen-2020-041479. BMJ Open. 2021. PMID: 33431491 Free PMC article.
Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017.
Kremer D, Glanzman R, Traboulsee A, Nath A, Groc L, Horwitz M, Göttle P, Perron H, Gold J, Hartung HP, Küry P. Kremer D, et al. Among authors: glanzman r. Mult Scler Relat Disord. 2017 Jul;15:18-23. doi: 10.1016/j.msard.2017.05.001. Epub 2017 May 1. Mult Scler Relat Disord. 2017. PMID: 28641767
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
Curtin F, Porchet H, Glanzman R, Schneble HM, Vidal V, Audoli-Inthavong ML, Lambert E, Hartung HP. Curtin F, et al. Among authors: glanzman r. Mult Scler Relat Disord. 2016 Sep;9:95-100. doi: 10.1016/j.msard.2016.07.002. Epub 2016 Jul 1. Mult Scler Relat Disord. 2016. PMID: 27645352 Clinical Trial.
20 results